DE60041715D1 - Verfahren zur herstellung von 1-benzotriazolcarbonatestern von wasserlöslichen polymeren - Google Patents
Verfahren zur herstellung von 1-benzotriazolcarbonatestern von wasserlöslichen polymerenInfo
- Publication number
- DE60041715D1 DE60041715D1 DE60041715T DE60041715T DE60041715D1 DE 60041715 D1 DE60041715 D1 DE 60041715D1 DE 60041715 T DE60041715 T DE 60041715T DE 60041715 T DE60041715 T DE 60041715T DE 60041715 D1 DE60041715 D1 DE 60041715D1
- Authority
- DE
- Germany
- Prior art keywords
- benzotriazolcarbonate
- starter
- preparing
- water
- soluble polymers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/91—Polymers modified by chemical after-treatment
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
- C08G65/48—Polymers modified by chemical after-treatment
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17183499P | 1999-12-22 | 1999-12-22 | |
PCT/US2000/034590 WO2001045796A2 (en) | 1999-12-22 | 2000-12-18 | Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol) |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60041715D1 true DE60041715D1 (de) | 2009-04-16 |
Family
ID=22625322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60041715T Expired - Lifetime DE60041715D1 (de) | 1999-12-22 | 2000-12-18 | Verfahren zur herstellung von 1-benzotriazolcarbonatestern von wasserlöslichen polymeren |
Country Status (14)
Country | Link |
---|---|
US (15) | US6376604B2 (de) |
EP (2) | EP2070968A3 (de) |
JP (2) | JP5095061B2 (de) |
KR (1) | KR100729977B1 (de) |
AT (1) | ATE424431T2 (de) |
AU (1) | AU781729B2 (de) |
CA (1) | CA2393638C (de) |
CY (1) | CY1109102T1 (de) |
DE (1) | DE60041715D1 (de) |
DK (1) | DK1259563T4 (de) |
ES (1) | ES2321800T5 (de) |
MX (1) | MXPA02006215A (de) |
PT (1) | PT1259563E (de) |
WO (1) | WO2001045796A2 (de) |
Families Citing this family (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100361933B1 (ko) * | 1993-09-08 | 2003-02-14 | 라 졸라 파마슈티칼 컴파니 | 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트 |
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
US6458953B1 (en) * | 1998-12-09 | 2002-10-01 | La Jolla Pharmaceutical Company | Valency platform molecules comprising carbamate linkages |
WO2000075105A1 (en) * | 1999-06-08 | 2000-12-14 | La Jolla Pharmaceutical Company | Valency platform molecules comprising aminooxy groups |
WO2001045796A2 (en) * | 1999-12-22 | 2001-06-28 | Shearwater Corporation | Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol) |
US6436386B1 (en) * | 2000-11-14 | 2002-08-20 | Shearwater Corporation | Hydroxyapatite-targeting poly (ethylene glycol) and related polymers |
US7829074B2 (en) | 2001-10-18 | 2010-11-09 | Nektar Therapeutics | Hydroxypatite-targeting poly(ethylene glycol) and related polymers |
US6765069B2 (en) * | 2001-09-28 | 2004-07-20 | Biosurface Engineering Technologies, Inc. | Plasma cross-linked hydrophilic coating |
CN105131104B (zh) | 2001-10-10 | 2018-11-16 | 诺和诺德公司 | 肽的重构和糖缀合 |
US8008252B2 (en) * | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
NZ532027A (en) | 2001-10-10 | 2008-09-26 | Neose Technologies Inc | Remodeling and glycoconjugation of peptides |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7173003B2 (en) * | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
JP2005534647A (ja) | 2002-06-07 | 2005-11-17 | ダイアックス、コープ | 失血の予防及び軽減 |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
DE60336555D1 (de) * | 2002-06-21 | 2011-05-12 | Novo Nordisk Healthcare Ag | Pegylierte glykoformen von faktor vii |
US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
KR20060003862A (ko) * | 2003-03-14 | 2006-01-11 | 네오스 테크놀로지스, 인크. | 수용성분기폴리머 및 그 접합체 |
US20060276618A1 (en) * | 2003-03-18 | 2006-12-07 | Defrees Shawn | Activated forms of water-soluble polymers |
WO2006127896A2 (en) * | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated factor ix |
US20070026485A1 (en) * | 2003-04-09 | 2007-02-01 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
US7932364B2 (en) * | 2003-05-09 | 2011-04-26 | Novo Nordisk A/S | Compositions and methods for the preparation of human growth hormone glycosylation mutants |
ES2725808T3 (es) * | 2003-05-23 | 2019-09-27 | Nektar Therapeutics | Derivados de PEG que contienen dos cadenas de PEG |
US7947261B2 (en) | 2003-05-23 | 2011-05-24 | Nektar Therapeutics | Conjugates formed from polymer derivatives having particular atom arrangements |
EP1656410B1 (de) | 2003-07-22 | 2010-03-10 | Nektar Therapeutics | Verfahren zur herstellung von funktionalisierten polymeren aus polymeralkoholen |
US20080026995A1 (en) * | 2003-07-25 | 2008-01-31 | Ac Immune Sa | Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers |
US7807171B2 (en) | 2003-07-25 | 2010-10-05 | Ac Immune Sa | Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
CA2536873C (en) * | 2003-08-29 | 2019-09-10 | Dyax Corp. | Poly-pegylated protease inhibitors |
US20080305992A1 (en) * | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US8633157B2 (en) * | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
EP1694347B1 (de) * | 2003-11-24 | 2013-11-20 | BioGeneriX AG | Glycopegyliertes Erythropoetin |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
US7956032B2 (en) | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
US20070254836A1 (en) * | 2003-12-03 | 2007-11-01 | Defrees Shawn | Glycopegylated Granulocyte Colony Stimulating Factor |
US20050153371A1 (en) * | 2004-01-07 | 2005-07-14 | Ambit Biosciences Corporation | Conjugated small molecules |
KR101439880B1 (ko) * | 2004-01-08 | 2014-09-12 | 라티오팜 게엠베하 | 펩티드의 오-결합형 글리코실화 |
AU2005211362B2 (en) | 2004-02-02 | 2008-03-13 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
AU2005319099B2 (en) * | 2004-02-02 | 2010-09-16 | Ambrx, Inc. | Modified human growth hormone |
PT2465533E (pt) * | 2004-02-20 | 2015-06-24 | Ac Immune Sa | Processos e composições que têm estruturas supramoleculares |
US7588745B2 (en) * | 2004-04-13 | 2009-09-15 | Si Options, Llc | Silicon-containing products |
EP1753805A4 (de) * | 2004-05-17 | 2009-11-25 | Univ Mcmaster | Gegenüber biologischen molekülen reaktive hydrophile silikonoberfläche |
CA2568952C (en) * | 2004-06-18 | 2019-05-21 | Ambrx, Inc. | Novel antigen-binding polypeptides and their uses |
EP1771066A2 (de) | 2004-07-13 | 2007-04-11 | Neose Technologies, Inc. | Remodellierung von verzweigtem peg und klykolysierung von glucagonähnlichem peptide-1 glp-1 |
AU2005275062A1 (en) | 2004-07-14 | 2006-02-23 | University Of Utah Research Foundation | Netrin-related compositions and uses |
MX2007000728A (es) * | 2004-07-21 | 2007-03-15 | Ambrx Inc | Polipeptidos biosinteticos que utilizan amino acidos no naturalmente codificados. |
US20090292110A1 (en) * | 2004-07-23 | 2009-11-26 | Defrees Shawn | Enzymatic modification of glycopeptides |
US8268967B2 (en) * | 2004-09-10 | 2012-09-18 | Novo Nordisk A/S | Glycopegylated interferon α |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
ES2572779T3 (es) | 2004-10-29 | 2016-06-02 | Ratiopharm Gmbh | Remodelación y glucopegilación del Factor de Crecimiento de Fibroblastos (FGF) |
NZ555386A (en) | 2004-12-22 | 2011-01-28 | Ambrx Inc | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
EP1836316A4 (de) | 2004-12-22 | 2009-07-22 | Ambrx Inc | Verfahren zur expression und reinigung von rekombinantem menschlichem wachstumshormon |
JP4990792B2 (ja) | 2004-12-22 | 2012-08-01 | アンブレツクス・インコーポレイテツド | アミノアシル−tRNAシンテターゼの組成物およびこの使用 |
JP2008526864A (ja) * | 2005-01-06 | 2008-07-24 | ネオス テクノロジーズ インコーポレイテッド | 糖断片を用いる糖結合 |
ES2449195T3 (es) | 2005-01-10 | 2014-03-18 | Ratiopharm Gmbh | Factor estimulante de colonias de granulocitos glicopegilado |
EP2386571B1 (de) | 2005-04-08 | 2016-06-01 | ratiopharm GmbH | Zusammensetzungen und Verfahren zur Herstellung von Glycosylierungsmutanten eines Proteaseresistenten menschlichen Wachstumshormons |
EP1888098A2 (de) * | 2005-05-25 | 2008-02-20 | Neose Technologies, Inc. | Glykopegylierte erythropoetin-formulierungen |
US20110003744A1 (en) * | 2005-05-25 | 2011-01-06 | Novo Nordisk A/S | Glycopegylated Erythropoietin Formulations |
ATE529442T1 (de) | 2005-06-03 | 2011-11-15 | Ambrx Inc | Verbesserte humane interferon-moleküle und ihre verwendungen |
ATE396692T1 (de) * | 2005-06-10 | 2008-06-15 | 3M Espe Ag | Dentalzusammensetzung enthaltend ein pre-polymer und einen vernetzer, verfahren zur produktion sowie deren verwendung |
EP2412744B1 (de) | 2005-07-18 | 2014-01-22 | Nektar Therapeutics | Verfahren zur Herstellung von verzweigten funktionalisierten Polymeren mithilfe von verzweigten Polyol-Kernen |
ES2529258T3 (es) * | 2005-07-29 | 2015-02-18 | Nektar Therapeutics | Métodos para preparar reactivos poliméricos |
US20070105755A1 (en) * | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
KR20080080081A (ko) * | 2005-08-19 | 2008-09-02 | 네오스 테크놀로지스, 인크. | 글리코페닐화 인자 ⅶ 및 인자 ⅶ에이 |
US20090048440A1 (en) * | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
EP1951890A4 (de) | 2005-11-16 | 2009-06-24 | Ambrx Inc | Verfahren und zusammensetzungen mit nichtnatürlichen aminosäuren |
US9187532B2 (en) | 2006-07-21 | 2015-11-17 | Novo Nordisk A/S | Glycosylation of peptides via O-linked glycosylation sequences |
DK2061878T3 (da) | 2006-09-08 | 2014-04-07 | Ambrx Inc | Hybridsuppressor-trna for hvirveldyrceller |
EP2615108B1 (de) | 2006-09-08 | 2016-10-26 | Ambrx, Inc. | Modifiziertes humanes Plasmapolypeptid oder Fc-Gerüste und deren Verwendungen |
MX2009002526A (es) | 2006-09-08 | 2009-04-16 | Ambrx Inc | Transcripcion de tarn supresor en celulas de vertebrados. |
EP2054521A4 (de) * | 2006-10-03 | 2012-12-19 | Novo Nordisk As | Verfahren zur reinigung von polypeptid-konjugate |
JP5457185B2 (ja) * | 2006-10-04 | 2014-04-02 | ノヴォ ノルディスク アー/エス | グリセロール連結のpeg化された糖および糖ペプチド |
US8101729B2 (en) * | 2007-03-19 | 2012-01-24 | Henry Joseph Niemczyk | Pegylated amino acid derivatives and the process to synthesize the same |
ATE554785T1 (de) | 2007-03-30 | 2012-05-15 | Ambrx Inc | Modifizierte fgf-21 polypeptide und ihre verwendung |
CA2682897C (en) | 2007-04-03 | 2016-11-22 | Biogenerix Ag | Methods of treatment using glycopegylated g-csf |
WO2008137471A2 (en) | 2007-05-02 | 2008-11-13 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
EP2162535A4 (de) * | 2007-06-04 | 2011-02-23 | Novo Nordisk As | O-verknüpfte glykosylierung unter verwendung von n-acetylglucosaminyl-transferasen |
CN101778859B (zh) * | 2007-06-12 | 2014-03-26 | 诺和诺德公司 | 改良的用于生产核苷酸糖的方法 |
US7968811B2 (en) * | 2007-06-29 | 2011-06-28 | Harley-Davidson Motor Company Group, Inc. | Integrated ignition and key switch |
US20090075887A1 (en) * | 2007-08-21 | 2009-03-19 | Genzyme Corporation | Treatment with Kallikrein Inhibitors |
US8207112B2 (en) * | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
EP2930182A1 (de) | 2007-11-20 | 2015-10-14 | Ambrx, Inc. | Modifizierte insulinpolypeptide und deren verwendungen |
SG188143A1 (en) | 2008-02-08 | 2013-03-28 | Ambrx Inc | Modified leptin polypeptides and their uses |
US20130189239A1 (en) | 2008-02-27 | 2013-07-25 | Novo Nordisk A/S | Conjugated Factor VIII Molecules |
US10138283B2 (en) | 2008-07-23 | 2018-11-27 | Ambrx, Inc. | Modified bovine G-CSF polypeptides and their uses |
WO2010033222A2 (en) * | 2008-09-19 | 2010-03-25 | Netkar Therapeutics | Polymer conjugates of ziconotide peptides |
EP2344200A2 (de) * | 2008-09-19 | 2011-07-20 | Nektar Therapeutics | Modifizierte therapeutische peptide, herstellungsverfahren und verwendung |
WO2010033216A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of nesiritide peptides |
EP2334337A1 (de) * | 2008-09-19 | 2011-06-22 | Nektar Therapeutics | Polymerkonjugate von opioid-wachstumsfaktor-peptiden |
US20110171166A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of osteocalcin peptides |
WO2010033224A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of kiss1 peptides |
US20110171161A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of protegrin peptides |
EP2344199A1 (de) * | 2008-09-19 | 2011-07-20 | Nektar Therapeutics | Polymer-konjugate von thymosin-alpha1-peptiden |
US20110171164A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of glp-2-like peptides |
WO2010033215A2 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of aod-like peptides |
EP2350118B1 (de) | 2008-09-19 | 2016-03-30 | Nektar Therapeutics | Kohlenhydratbasisierte polymere zur wirkstoffabgabe und konjugate davon |
EP2334338A2 (de) * | 2008-09-19 | 2011-06-22 | Nektar Therapeutics | Polymerkonjugate von c-peptiden |
WO2010033205A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of v681-like peptides |
CN102232085A (zh) | 2008-09-26 | 2011-11-02 | Ambrx公司 | 修饰的动物促红细胞生成素多肽和其用途 |
MX2011003196A (es) | 2008-09-26 | 2011-04-27 | Ambrx Inc | Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales. |
AU2010203712A1 (en) | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
US8975445B2 (en) * | 2009-04-06 | 2015-03-10 | Solvay Specialty Polymers Italy S.P.A. | Process for the manufacture of functional PFPE derivative |
AU2010258752B2 (en) | 2009-06-09 | 2015-07-09 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
EP2507381A4 (de) | 2009-12-04 | 2016-07-20 | Hoffmann La Roche | Multispezifische antikörper, antikörperanaloge, zusammensetzungen und verfahren |
BR112012015597A2 (pt) | 2009-12-21 | 2017-01-31 | Ambrx Inc | peptídeos de somatotropina suínos modificados e seus usos |
MX349301B (es) | 2009-12-21 | 2017-07-21 | Ambrx Inc | Polipéptidos de somatotropina bovina modificados y sus usos. |
SI2521568T1 (sl) | 2010-01-06 | 2019-01-31 | Dyax Corp. | Proteini, ki vežejo plazemski kalikrein |
WO2012020124A1 (en) | 2010-08-12 | 2012-02-16 | Ac Immune S.A. | Vaccine engineering |
HUE045845T2 (hu) | 2010-08-17 | 2021-12-28 | Ambrx Inc | Módosított relaxin polipeptidek és felhasználásuk |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
AR083006A1 (es) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas |
WO2012054822A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Pharmacologically active polymer-glp-1 conjugates |
TW201223561A (en) | 2010-10-26 | 2012-06-16 | Ac Immune Sa | Preparation of an antigenic construct |
CN103635489B (zh) | 2011-01-06 | 2016-04-13 | 戴埃克斯有限公司 | 血浆前激肽释放酶结合蛋白 |
AU2013270684B2 (en) | 2012-06-08 | 2018-04-19 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
DK2863955T3 (en) | 2012-06-26 | 2017-01-23 | Sutro Biopharma Inc | MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF |
ES2907763T3 (es) | 2012-08-31 | 2022-04-26 | Sutro Biopharma Inc | Aminoácidos modificados que comprenden un grupo azido |
ES2658039T3 (es) | 2013-07-10 | 2018-03-08 | Sutro Biopharma, Inc. | Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso |
WO2015054658A1 (en) | 2013-10-11 | 2015-04-16 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
CN106459210A (zh) | 2014-03-27 | 2017-02-22 | 戴埃克斯有限公司 | 用于治疗糖尿病黄斑性水肿的组合物和方法 |
EA036697B1 (ru) | 2014-10-24 | 2020-12-09 | Бристол-Майерс Сквибб Компани | Модифицированные полипептиды fgf-21 и их применение |
EA201891388A1 (ru) | 2015-12-11 | 2018-11-30 | Дайэкс Корп. | Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека |
CA3052639A1 (en) | 2017-02-08 | 2018-08-16 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
FI3849614T3 (fi) | 2018-09-11 | 2024-02-08 | Ambrx Inc | Interleukiini-2-polypeptidikonjugaatteja ja niiden käyttöjä |
EP3864068A2 (de) * | 2018-10-11 | 2021-08-18 | Nektar Therapeutics | Verfahren zur herstellung von freisetzbaren polymeren reagenzien |
JP2022512746A (ja) | 2018-10-19 | 2022-02-07 | アンブルックス,インコーポレイテッド | インターロイキン-10ポリペプチド複合体、その二量体、およびそれらの使用 |
BR112021015832A2 (pt) | 2019-02-12 | 2022-01-18 | Ambrx Inc | Composições que contêm conjugados de anticorpo-agonista de tlr, métodos e usos dos mesmos |
AU2021233909A1 (en) | 2020-03-11 | 2022-09-29 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
AU2021327396A1 (en) | 2020-08-20 | 2023-03-23 | Ambrx, Inc. | Antibody-TLR agonist conjugates, methods and uses thereof |
WO2022212899A1 (en) | 2021-04-03 | 2022-10-06 | Ambrx, Inc. | Anti-her2 antibody-drug conjugates and uses thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE287951C (de) | ||||
KR850001206B1 (ko) | 1984-04-27 | 1985-08-20 | 한국과학기술원 | 세펨 유도체의 제조 방법 |
JPS62181269A (ja) * | 1986-02-06 | 1987-08-08 | Haruo Ogura | 新規な活性エステル化剤化合物 |
DD287951A5 (de) † | 1989-09-15 | 1991-03-14 | Adw Zi F. Molekularbiologie,De | Verfahren zur immobilisierung biologisch aktiver verbindungen an polyoxyalkylenglykole und ihre monoalkoxyderivate |
US5281698A (en) † | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
US5629384A (en) | 1994-05-17 | 1997-05-13 | Consiglio Nazionale Delle Ricerche | Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces |
US5650234A (en) † | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US6229002B1 (en) | 1995-06-07 | 2001-05-08 | Nexstar Pharmaceuticlas, Inc. | Platelet derived growth factor (PDGF) nucleic acid ligand complexes |
US5985263A (en) * | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
ES2307865T3 (es) * | 1998-03-12 | 2008-12-01 | Nektar Therapeutics Al, Corporation | Metodo para preparar conjugados polimericos. |
US6348558B1 (en) * | 1999-12-10 | 2002-02-19 | Shearwater Corporation | Hydrolytically degradable polymers and hydrogels made therefrom |
WO2001045796A2 (en) | 1999-12-22 | 2001-06-28 | Shearwater Corporation | Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol) |
US6436386B1 (en) * | 2000-11-14 | 2002-08-20 | Shearwater Corporation | Hydroxyapatite-targeting poly (ethylene glycol) and related polymers |
TW593427B (en) * | 2000-12-18 | 2004-06-21 | Nektar Therapeutics Al Corp | Synthesis of high molecular weight non-peptidic polymer derivatives |
WO2004074345A2 (en) * | 2003-02-19 | 2004-09-02 | Pharmacia Corporation | Carbonate esters of polyethylene glycol activated by means of oxalate esters |
FR2876461B1 (fr) * | 2004-10-07 | 2006-12-29 | Commissariat Energie Atomique | Systeme optique a extension de propagation de faisceau. |
-
2000
- 2000-12-18 WO PCT/US2000/034590 patent/WO2001045796A2/en active IP Right Grant
- 2000-12-18 DE DE60041715T patent/DE60041715D1/de not_active Expired - Lifetime
- 2000-12-18 AT AT00986602T patent/ATE424431T2/de active
- 2000-12-18 EP EP09154211.8A patent/EP2070968A3/de not_active Withdrawn
- 2000-12-18 JP JP2001546734A patent/JP5095061B2/ja not_active Expired - Lifetime
- 2000-12-18 AU AU22810/01A patent/AU781729B2/en not_active Expired
- 2000-12-18 KR KR1020027008016A patent/KR100729977B1/ko active IP Right Grant
- 2000-12-18 PT PT00986602T patent/PT1259563E/pt unknown
- 2000-12-18 EP EP00986602.1A patent/EP1259563B2/de not_active Expired - Lifetime
- 2000-12-18 MX MXPA02006215A patent/MXPA02006215A/es active IP Right Grant
- 2000-12-18 ES ES00986602.1T patent/ES2321800T5/es not_active Expired - Lifetime
- 2000-12-18 US US09/740,556 patent/US6376604B2/en not_active Expired - Lifetime
- 2000-12-18 DK DK00986602.1T patent/DK1259563T4/en active
- 2000-12-18 CA CA002393638A patent/CA2393638C/en not_active Expired - Lifetime
-
2002
- 2002-02-06 US US10/068,349 patent/US6624246B2/en not_active Expired - Lifetime
- 2002-02-06 US US10/068,371 patent/US6710125B2/en not_active Expired - Lifetime
-
2003
- 2003-12-02 US US10/727,337 patent/US7101932B2/en not_active Expired - Lifetime
-
2006
- 2006-07-24 US US11/492,133 patent/US7378469B2/en not_active Expired - Lifetime
-
2008
- 2008-04-25 US US12/150,136 patent/US7544738B2/en not_active Expired - Lifetime
-
2009
- 2009-04-30 US US12/433,874 patent/US7723432B2/en not_active Expired - Fee Related
- 2009-05-28 CY CY20091100563T patent/CY1109102T1/el unknown
-
2010
- 2010-04-08 US US12/756,905 patent/US7977427B2/en not_active Expired - Fee Related
-
2011
- 2011-06-07 US US13/154,917 patent/US8299173B2/en not_active Expired - Lifetime
-
2012
- 2012-03-22 JP JP2012065779A patent/JP2012122080A/ja not_active Withdrawn
- 2012-10-30 US US13/664,021 patent/US8563651B2/en not_active Expired - Fee Related
-
2013
- 2013-10-21 US US14/059,020 patent/US8816002B2/en not_active Expired - Fee Related
-
2014
- 2014-08-25 US US14/467,634 patent/US9346917B2/en not_active Expired - Lifetime
-
2016
- 2016-04-22 US US15/136,632 patent/US9839695B2/en not_active Expired - Fee Related
-
2017
- 2017-11-08 US US15/807,335 patent/US10456476B2/en not_active Expired - Fee Related
-
2019
- 2019-09-20 US US16/578,141 patent/US20200009260A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60041715D1 (de) | Verfahren zur herstellung von 1-benzotriazolcarbonatestern von wasserlöslichen polymeren | |
DE69914611T2 (de) | Verfahren zur herstellung von polyamidketten von genauer länge und deren konjugate mit proteinen | |
DE69939033D1 (de) | Verfahren zur Herstellung von Polymerkonjugaten | |
EA200500519A1 (ru) | Полимерные конъюгаты с пониженными антигенными свойствами, способы их получения и применения | |
RU2002120486A (ru) | Свободная от агрегатов уратоксидаза для приготовления неиммуногенных полимерных конъюгатов | |
KR960705869A (ko) | 수용성의 활성 술폰을 갖는 폴리 (에틸렌글리콜) (water soluble active sulfones of poly(ethylene glycol) | |
DK1028753T3 (da) | Indgivelse af poly(ethylenglycol)-konjugerede molekyler fra nedbrydellige hydrogeler | |
DE69938435D1 (de) | Niedrigallergene Proteinvarianten | |
HUT60512A (en) | Process for producing polyethylene glycol conjugates of proteins | |
DE69316278D1 (de) | Verfahren zur Herstellung von Polysuccinimidpolymeren | |
ATE290564T1 (de) | Funktionsfähige poly-alpha-aminosäurederivate zur modifizierung von biologisch wirksamen stoffen und deren herstellung | |
EA200300852A1 (ru) | Конъюгаты нейбластина с полимерами и способы их применения | |
DE60123226D1 (de) | Hydrogele und verfahren zur herstellung davon | |
DE60313786D1 (de) | Poly(ethylen glykol)-konjugate von insulinähnlichem wachstumfaktor bindenden protein-4 | |
ATE512217T1 (de) | 5-substituerte hydantoin racemase, dafür kodierende dna, und verfahren zur herstellung optisch aktiver aminosäure | |
EP0844252A3 (de) | Zyklische Peptide mit einer zur anschliessenden chemischen Kupplung entworfenen Zweiggruppe und Verfahren zu deren Herstellung | |
ATE251121T1 (de) | Verfahren zur herstellung von 1,3,6- hexantricarbonitril | |
DE60104381D1 (de) | Verfahren zur Herstellung von einer Amid Verbindung | |
ATE95207T1 (de) | Verfahren zur herstellung eines thermoplastisch verarbeitbaren, aromatischen polyamids. | |
DE60027833D1 (de) | Verfahren zur Herstellung von Polyasparaginsäure | |
DE60025096D1 (de) | Verfahren zur herstellung von n,n'-dialkylalkandiaminen | |
EP1400551B1 (de) | Polyamideketten von genauer Länge und deren Konjugate mit Proteinen | |
DE50302638D1 (de) | Verfahren zur Herstellung von stabilisiertem Polyamid 6 | |
DE60222835D1 (de) | Verfahren zur herstellung von 1,3-bis(3-aminophenoxy)benzol | |
DE60100871D1 (de) | Verfahren zur Herstellung von Alkylendiamin-N,N'-Dibernsteinsäure-Eisen-Base Komplex mit pH-Kontrolle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: NEKTAR THERAPEUTICS (N.D.GES.D. STAATES DELAWA, US |